Cholangiocarcinoma: Risk Factors, Diagnostic Tools, and Current Treatment Options
DOI:
10.29303/jbt.v23i4.5741Published:
2023-10-16Downloads
Abstract
Cholangiocarcinoma is a disease caused by the differentiation of cells in the bile epithelium or liver parenchyma into malignant cells called cholangiocytes. This literature review presents the current risk factors, diagnostic tools, and treatment choices of cholangiocarcinoma. Publication about the current risk factors, diagnostic tools, and treatment choices of cholangiocarcinoma were collected from the Pubmed database until August 25, 2022. The keywords of the research were “cholangiocarcinoma”, “risk factor”, “diagnostic”, and “treatment”. Cholangiocarcinoma has many risk factors, from choledochal cysts, and primary sclerosing cholangitis, to asbestos exposure. The diagnosis of cholangiocarcinoma is difficult and requires the combined interpretation of different diagnostic modalities. Examinations that can be done for the diagnosis and staging of cholangiocarcinoma are MRI and CT. However, if the diagnosis remains uncertain, endoscopic examination and tissue sampling may be performed. After the diagnosis, there are several treatments, namely surgical therapy (surgical excision of bile duct tumors), endoscopic therapy (endoscopic biliary dilatation), radiological therapy (percutaneous transhepatic palliative biliary dilatation), chemotherapy and radiotherapy, and photodynamic therapy. Cholangiocarcinoma is a malignancy of cells in the biliary epithelium or liver parenchyma (cholangiocytes) that has many risk factors. The diagnosis of cholangiocarcinoma is difficult and requires a combined interpretation of the different diagnostic modalities, including MRI, CT, endoscopy, and tissue sampling. After the diagnosis, there are several treatments, namely surgical therapy, endoscopy, radiology therapy, chemotherapy and radiotherapy, and photodynamic therapy.
Keywords:
Cholangiocarcinoma, diagnostic, risk factor, and treatment.References
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., Calvisi, D. F., Perugorria, M. J., Fabris, L., Boulter, L., Macias, R. I. R., Gaudio, E., Alvaro, D., Gradilone, S. A., Strazzabosco, M., … Gores, G. J. (2020). Cholangiocarcinoma 2020: the next horizon in mechanisms and management. In Nature Reviews Gastroenterology and Hepatology (Vol. 17, Issue 9, pp. 557–588). Nature Research. DOI: https://doi.org/10.1038/s41575-020-0310-z
Blechacz, B. (2017). Cholangiocarcinoma: Current knowledge and new developments. In Gut and Liver (Vol. 11, Issue 1, pp. 13–26). Joe Bok Chung. DOI: https://doi.org/10.5009/gnl15568
Brindley, P. J., Bachini, M., Ilyas, S. I., Khan, S. A., Loukas, A., Sirica, A. E., Teh, B. T., Wongkham, S., & Gores, G. J. (2021). Cholangiocarcinoma. In Nature Reviews Disease Primers (Vol. 7, Issue 1). Nature Research. DOI: https://doi.org/10.1038/s41572-021-00300-2
Cai, H. et al. (2015) ‘Cholelithiasis and the risk of intrahepatic cholangiocarcinoma: A meta-analysis of observational studies’, BMC Cancer, 15(1). DOI: https://doi.org/10.1186/s12885-015-1870-0.
Doherty, B., Nambudiri, V. E., & Palmer, W. C. (2017). Update on the Diagnosis and Treatment of Cholangiocarcinoma. In Current Gastroenterology Reports (Vol. 19, Issue 1). Current Medicine Group LLC 1. DOI: https://doi.org/10.1007/s11894-017-0542-4
Donahoe (2012) “基因的改变NIH Public Access,” Molecular and Cellular Biochemistry, 23(1), pp. 1–7. DOI: 10.1038/nrgastro.2011.131.Clinical.
Huai, J.P. et al. (2014) ‘Inflammatory bowel disease and risk of cholangiocarcinoma: Evidence from a meta-analysis of population-based studies’, Asian Pacific Journal of Cancer Prevention, 15(8), pp. 3477–3482. DOI: https://doi.org/10.7314/APJCP.2014.15.8.3477.
Khan, S.A., Tavolari, S. and Brandi, G. (2019) ‘Cholangiocarcinoma: Epidemiology and risk factors’, Liver International. Blackwell Publishing Ltd, pp. 19–31. DOI: https://doi.org/10.1111/liv.14095.
Palmer, W.C. and Patel, T. (2012) ‘Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma’, Journal of Hepatology, 57(1), pp. 69–76. DOI: https://doi.org/10.1016/j.jhep.2012.02.022.
Parsi, M.A. (2013) ‘Obesity and cholangiocarcinoma’, World Journal of Gastroenterology, 19(4), pp. 457–462. DOI: https://doi.org/10.3748/wjg.v19.i4.457.
Reddy, S.K. et al. (2013) ‘Prevalence of Nonalcoholic Steatohepatitis Among Patients with Resectable Intrahepatic Cholangiocarcinoma’, Journal of Gastrointestinal Surgery, 17(4), pp. 748–755. DOI: https://doi.org/10.1007/s11605-013-2149-x.
Rizvi, S. et al. (2018) ‘Cholangiocarcinoma-evolving concepts and therapeutic strategies’, Nature Reviews Clinical Oncology. Nature Publishing Group, pp. 95–111. DOI: https://doi.org/10.1038/nrclinonc.2017.157.
Sripa, B., Deenonpoe, R. and Brindley, P.J. (2017) ‘Co-infections with liver fluke and Helicobacter species: A paradigm change in pathogenesis of opisthorchiasis and cholangiocarcinoma?’, Parasitology International. Elsevier Ireland Ltd, pp. 383–389. DOI: https://doi.org/10.1016/j.parint.2016.11.016.
Van Beers, B. E. (2014) “Diagnosis of cholangiocarcinoma,” Hpb, 10(2), pp. 87–93. DOI: 10.1080/13651820801992716.
Vogel, A. et al. (2014) “The diagnosis and treatment of cholangiocarcinoma,” Deutsches Ärzteblatt international, 111(44), pp. 748–754. DOI: 10.3238/arztebl.2014.0748.
Ye, X.H. et al. (2013) ‘Smoking, alcohol consumption, and the risk of extrahepatic cholangiocarcinoma: A meta-analysis’, World Journal of Gastroenterology, 19(46), pp. 8780–8788. Available at: https://doi.org/10.3748/wjg.v19.i46.8780.
Zhang, Hao et al. (2016) ‘HBV Infection Status and the Risk of Cholangiocarcinoma in Asia: A Meta-Analysis’, BioMed Research International, 2016. DOI: https://doi.org/10.1155/2016/3417976.
License
Copyright (c) 2023 Adli Putra Nugraha, Baiq Ghassani Kayla, Febbi Anggy, Ni Made Utami Wulandari, Wina Arsylia Fakar, Philip Habib
This work is licensed under a Creative Commons Attribution 4.0 International License.
Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.
